tbuckley/cabot-search huggingface dataset:
The impact of regional anesthesia on bladder cancer outcomes.
Authors: Jamie RiChard, Michael Lipsky, Michael Whalen, Piruz Motamedinia, Julia Finkelstein, Gregory Hruby, Guarionex DeCastro, Saundra Curry, Mitchell C. Benson, James M. McKiernan
Journal: Journal of Clinical Oncology (2012)

e15021 Background: Studies in breast and prostate surgery show reduced cancer recurrence after regional (RA) versus general anesthesia (GA). Mechanisms include RAÕs reduced post-operative opioid use and cortisol-mediated immunosuppression. RA may be used alone during transurethral resection of bladder tumors (TURBT) and in combination with GA during radical cystectomy (RC). We assess the impact of RA on short-term bladder urothelial cell carcinoma (UCC) recurrence after TURBT or RC. Methods: From 8/2001 and 6/2006 to 6/2011, 151 patients underwent RC and 488 patients underwent TURBT for bladder UCC, respectively. Those with incomplete resection on TURBT were excluded. Anesthesia included RA or GA for TURBT, and GA alone or GA + RA for RC. Multivariate logistic regression was performed to identify significant predictors of biopsy- or radiography-confirmed UCC recurrence. Results: TURBT. Of 252 patients, 211 received GA and 41 received RA during TURBT. Patient and operative characteristics were similar between groups. Recurrence was 56% at 12 months for GA and RA. Multivariate analysis revealed clinical stage to be the only predictor of UCC recurrence (HR=1.8, p&lt;0.0001). Anesthesia had no affect on 6 or 12 month RFS, DSS or OS (see table). RC. GA was used in 114 patients and 37 patients had GA + RA at RC. There were no between group differences in patient or tumor characteristics. After follow-up of 18 months, 25.9% and 21.6% recurred in GA and GA+RA groups, respectively (p&gt;0.05). There were no differences in RFS, DSS, or OS (see Table). Conclusions: Contrary to other malignancies, our data suggest anesthesia type at TURBT or RC does not affect bladder cancer outcomes. Anesthesia modality should be based on patient comorbidities and procedure type. [Table: see text]
A phase I study of docetaxel/oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction
Authors: K. Hosoda, M. Azuma, C. Katada, K. Ishido, M. Niihara, H. Ushiku, M. Sakuraya, M. Washio, T. Wada, A. Watanabe, H. Harada, S. Tanabe, W. Koizumi, K. Yamashita, N. Hiki, M. Watanabe
Journal: Annals of Oncology (2019)
Association of Patient Priorities–Aligned Decision-Making With Patient Outcomes and Ambulatory Health Care Burden Among Older Adults With Multiple Chronic Conditions
Authors: Mary E. Tinetti, Aanand D. Naik, Lilian Dindo, Darce M. Costello, Jessica Esterson, Mary Geda, Jonathan Rosen, Kizzy Hernandez-Bigos, Cynthia Daisy Smith, Gregory M. Ouellet, Gina Kang, Yungah Lee, Caroline Blaum
Journal: JAMA Internal Medicine (2019)

Health care may be burdensome and of uncertain benefit for older adults with multiple chronic conditions (MCCs). Aligning health care with an individual's health priorities may improve outcomes and reduce burden.
Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Data from the prospective PROREPAIR-B study
Authors: C. Cattrini, N Romero Laorden, E. Castro, I. García-Carbonero, J.M. Piulats, J. Puente, B.P. Valderrama, J C Villa Guzman, E Gonzalez Billalabeitia, R Morales Barrera, R Lozano Mejorada, R. Luque, E Martinez Ortega, J A Arranz Arija, E Gallardo Diaz, A Pinto Marin, E Almagro Casado, M J Mendez Vidal, D Olmos Hidalgo, D. Lorente
Journal: Annals of Oncology (2019)
CCND1 amplification contributes to immunosuppression in head and neck squamous cell carcinoma and the association with a poor response to immune checkpoint inhibitors
Authors: C. Huang, Y. Chen, X. Gao, Y. Li, J. Lin, L.Z. Chen, L.P. Chang, G. Chen, Y.F. Guan, L.K. Pan, X.F. Xia, Z.Q. Guo, J.J. Pan, X. Yi, C.B. Chen
Journal: Annals of Oncology (2019)
Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer
Authors: V.C. Diéras, H.S. Han, B. Kaufman, H. Wildiers, M. Friedlander, J.-P. Ayoub, S.L. Puhalla, I. Bondarenko, M. Campone, E.H. Jakobsen, M. Jalving, C. Oprean, M. Palácová, Y.H. Park, Y. Shparyk, E. Yañez, M. Dudley, C.K. Ratajczak, D. Maag, B.K. Arun
Journal: Annals of Oncology (2019)
Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm+) advanced NSCLC: Updated data from the GioTag real-world study
Authors: M.J. Hochmair, A. Morabito, D. Hao, C.-T. Yang, R. Soo, J C-H Yang, R. Gucalp, B. Halmos, L. Wang, A. Golembesky, A. Märten, T. Cufer
Journal: Annals of Oncology (2019)
JFMC51-1702-C7: Phase II study investigating efficacy and safety of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) in patients (pts) with metastatic colorectal cancer (mCRC) refractory or intolerant to standard chemotherapies
Authors: K. Kazama, M. Nakamura, R. Tanaka, H. Ojima, A. Makiyama, N. Matsuhashi, Y. Kagawa, H. Okuda, M. Asayama, Y. Yuasa, Y. Negoro, H. Mushiake, D. Manaka, K. Oba, T. Yoshino, K. Yoshida, Y. Maehara, K. Yamazaki, E. Oki, T. Takahashi
Journal: Annals of Oncology (2019)
AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)
Authors: C. Cardone, B. Blauensteiner, V. Moreno-Viedma, P.P. Vitiello, G. Martini, D. Ciardiello, V. Simeon, A.M. Rachiglio, D. Rizzi, E. Maiello, T. Latiano, C. Cremolini, G. Argiles Martinez, E. Elez, A. Falcone, J. Tabernero, N. Normanno, M. Sibilia, F. Ciardiello, E. Martinelli
Journal: Annals of Oncology (2019)
Abstract 3179: The Association Between Patient Cardiac Risk Factors and Referral Practices to Cardiac Rehabilitation
Authors: Ammar Habib, Donna M Buchanan, Kimberly J Reid, John A Spertus
Journal: Circulation (2008)

Despite the overwhelming evidence showing the benefits of cardiac rehabilitation (CR) after Myocardial Infarction (MI), it remains highly underutilized. Limited information is available describing patient characteristics and treatments associated with CR referral practices. The study included 2294 patients from 17 US sites in the PREMIER registry that were discharged home after MI. Predictors of CR referral were determined using a multivariable hierarchical modified Poisson regression model with site-centered variables, which accounted for both clustering of patients within a hospital and confounding due to the hospital. Clinically pertinent variables were chosen a priori for inclusion in the multivariable model. Of patients discharged home, only 49.5% received referral to CR programs. Multivariable-adjusted results revealed patients with a history of chronic heart failure or coronary artery disease and those that arrived at the hospital with an acute non-cardiac condition were less likely to be referred to CR (Table ). Moreover other characteristics identifying patients with a strong indication for CR (e.g. smoking, less education and the presence of other comorbid diseases) were not more likely to be referred to CR. Despite existing evidence of the significant benefits of CR after MI, less than half of patients discharged home were referred to CR programs. Importantly, those with the greatest potential to benefit from CR programs were not more likely to be referred. Since CR remains underutilized by healthcare professionals, it is important to further explore barriers to CR referral and educate physicians about CR benefits to improve the implementation of the new AACVPR/ACC/AHA 2007 performance measure on CR referral. Table: Relative Risk of Referral to Cardiac Rehab after MI
Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL
Authors: T.Q.G. Eisen, E. Frangou, B. Smith, A. Ritchie, R.S. Kaplan, B. Oza, I.D. Davis, M.R. Stockler, L. Albiges, B. Escudier, J.M.G. Larkin, A. Bex, S. Joniau, B.W. Hancock, G.G. Hermann, J. Bellmunt, E. Hodgkinson, P. Hanlon, M.K.B. Parmar, A.M. Meade
Journal: Annals of Oncology (2019)
Integrated population pharmacokinetic modelling of liposomal irinotecan in patients with various tumour types, including untreated metastatic pancreatic cancer (mPC)
Authors: T. Macarulla, K. Brendel, C. Lieu, Z. Wainberg, F. Dayyani, B. Zhang, B. Belanger, Y. Moore, A. Pedret-Dunn, F. Maxwell, A. Dean
Journal: Annals of Oncology (2019)
My Summer Vacation
Authors: Margaret Tempero
Journal: Journal of the National Comprehensive Cancer Network (2019)

My Summer Vacation B y the time you read this, summer will be a distant memory.Fall colors will be glowing across the country, and we will all be thinking about how and with whom to spend the winter holidays.But as I write this, I am reflecting on my short vacation at the end of August and wondering what I did wrong.I suspect we all approach our vacations the same way.After planning the vacation and scheduling time away from the office and clinic, we must get ready to actually be away.For most of us, this means finding people to cover patients, administrative duties, and any other responsibilities.Then we work to get caught up on paperwork and other looming deadlines so that we can leave with a clear conscience.By the time we leave, we're exhausted!We arrive at our destination drained and need to rest up.But that's OK, isn't it?After all, isn't that what a vacation is for?But wait!You also wanted to hike or bike or visit friends or do any of a million things you never get to do during a regular work week.Ok, maybe you can fit these things in later in the week.After all, a week is a nice chunk of time for a vacation, right?Meanwhile, you've told your colleagues that you are going on vacation and you've carefully put a vacation message on your email.Anyone who knows you well would surely text or call if they really needed you.So, you promise yourself that you will NOT look at your email.But after over 500 unread messages pile up, you give in-just to "clean it up," and of course, to flag important emails to follow up on later. . .after vacation.But then you notice that your biggest program benefactor needs some advice, several patients have been hospitalized, and a colleague has a time-sensitive issue.So, you follow up.Then you follow up again.And again.Before you know it, it is time to head home.When you get there, all the other work you should have done during the week will be waiting for you.And the cycle starts again.As oncologists, we have intense and emotional jobs.Burnout is common.But getting the right balance of free and unencumbered time is tough.The pace of activities in our world doesn't stop when we need a break, and rapid turnaround in communication is expected these days.And I don't think that's going to change.I'm not sure what the right answer is.I have a colleague who goes on vacation for a month each year and his out-of-office message is simple: "I'm on vacation.Email me again when I get back."Although I think that might be a bit extreme, I'll bet he's pretty rested when he returns!As for me, I'm going to stop kidding myself that a week is enough time to recharge.If any of you have figured out how to do this right, let me know.And in case you are wondering, the week wasn't a total loss.I took golf lessons.Now I just need to find time to play.
Evaluating the prevalence of the expression of PD-L1 in NSCLC specimens with short-duration formalin fixation using IHC 22C3 pharmDx
Authors: K. Ota, T. Ueno, T. Nakanishi, T. Nakano, T. Yamashita, M. Yoshimi, A. Fujita, H. Okabayashi, Y. Tao, S. Takata
Journal: Annals of Oncology (2019)
Neoadjuvant endocrine therapy with palbociclib in patients with high-risk breast cancer
Authors: P.E. Lønning, C. Clausen, E.S. Blix, S. Lundgren, G. Vagstad, H. Espelid, B. Gilje, E.A. Janssen, J. Geisler, T. Aas, H. Aase, S. Knappskog, H.P. Eikesdal
Journal: Annals of Oncology (2019)
Inadequacy of current definition and staging system of Medication-Related Osteonecrosis of Jaw (MRONJ) released by AAOMS: A computed tomography study in 151 cancer and myeloma patients
Authors: V. Fusco, A. Fasciolo, A. Gambino, M. Cabras, F. Erovigni, C. Bianchi, L. Benzi, I. De Martino, F. Monaco, M. Rossi, G. Numico, S. Carossa
Journal: Annals of Oncology (2019)
Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials
Authors: G. Werutsky, M. Untch, C. Hanusch, P.A. Fasching, J.-U. Blohmer, S. Seiler, C. Denkert, H. Tesch, C. Jackisch, B. Gerber, A. Schneeweiss, T. Link, J. Huober, K. Rhiem, V. Vladimirova, V. Nekljudova, S. Loibl
Journal: Annals of Oncology (2019)
Blood-based TMB (bTMB) correlates with tissue-based TMB (tTMB) in a multi-cancer phase I IO cohort
Authors: D.V. Araujo, A. Wang, D. Torti, J. Huang, A. Leon, K. Marsh, A. McCarthy, H. Berman, A. Spreafico, A.R. Hansen, A.A. Razak, P. Bedard, L. Wang, E. Plackmann, H. Chow, H. Bao, X. Wu, T.J. Pugh, L.L. Siu
Journal: Annals of Oncology (2019)
Epidemiological Vocabulary
Authors: HERBERT L. ECKERT
Journal: Annals of Internal Medicine (1974)

Comments1 November 1974Epidemiological VocabularyHERBERT L. ECKERT, M.D.HERBERT L. ECKERT, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-81-5-713_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: You and Drs. Weitzman and Berger are to be commended for the relevance you bring to analytic epidemiology in the paper, "Clinical Trial Design in Studies of Corticosteroids for Bacterial Infections" (Ann Intern Med 81:36-42, 1974). It helps to fill a void in a paradoxical aspect of the medical school curricula, which expose the preclinical students to the theories of epidemiology but examine the students (National Boards or FLEX) after their clinical years. As the article implies, there may be little application of epidemiologic fundamentals in the clinical or postgraduate years of medical training.My concerns about...References1. MACMAHON B and PUGH T: Epidemiology, Principles and Methods. Boston, Little, Brown and Company, 1970, p. 41-42 Google Scholar2. See Reference 1, p. 207-208 Google Scholar3. FEINSTEIN A: Clinical biostatistics. X. Sources of 'transition bias' in cohort statistics. Clin Pharmacol Ther 12:704-706, 1971 CrossrefMedlineGoogle Scholar4. FEINSTEIN A: Clinical biostatistics. XI. Sources of 'chronology bias' in cohort statistics. Clin Pharmacol Ther 12:864-879, 1971 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: HERBERT L. ECKERT, M.D.Affiliations: Division of Public Health and Preventive Medicine West Virginia University School of Medicine Infectious Disease Branch ALFORD Morgantown, WV 26505 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 November 1974Volume 81, Issue 5Page: 713-713KeywordsClinical epidemiologyClinical trials ePublished: 1 December 2008 Issue Published: 1 November 1974 PDF downloadLoading ...
Abstract 11416: The “Natural History” of Intra-operative Pulmonary Artery Stents: A 20-year Perspective
Authors: Jeffrey D Zampi, Emefah Loccoh, Aimee K Armstrong, Sunkyung Yu, Ray Lowery, Albert Rocchini, Jennifer C Hirsch-Romano
Journal: Circulation (2015)

Background: Branch pulmonary artery (PA) stenoses are typically treated with catheter-based percutaneous therapies or surgical arterioplasty. Intra-operative (intra-op) PA stent placement is an alternative strategy. In this study, we sought to describe our 20-year experience with intra-op PA stent placement and to evaluate long-term patient outcomes, specifically the need and risk factors for re-intervention. Methods: We performed a retrospective review of all intra-op PA stents placed at our institution from 1994-2013. Patient and stent characteristics and outcome data were collected. Risk factors associated with re-intervention were identified using univariate cox regression analysis. Results: Eighty-one PA stents were placed in 68 patients, mostly to treat proximal PA stenoses (85%). Stent implantation was acutely successful in 67 patients (98.5%) with a procedural complication rate of 4.4%. Stents capable of being dilated to large diameters (“adult-size”) were used in 97% of patients. At hospital discharge, 93% of patients had no or mild residual PA stenosis by echocardiogram. During a median follow-up period of 6 years (interquartile range 0.9-12.7), 31 patients (46%) underwent PA re-intervention with a median time to first re-intervention of 2.5 years. Risk factors for re-intervention included age &lt; 18 months (Hazard ratio [HR] 3.26, p=0.002) and body surface area &lt; 0.47 m2 (HR 3.47, p=0.001) at the time of stent implantation, and the presence of multiple aorto-pulmonary collaterals in patients with tetralogy of Fallot (HR 3.19, p=0.02). Conclusions: Intra-op PA stent implantation is technically feasible with low procedural complications. It offers several advantages over transcatheter stenting, including the ability to implant adult-size stents in small patients while avoiding injury to percutaneous vessels, to position and flare stents to facilitate future percutaneous stent re-dilation, and to access the PAs directly, which shortens procedural time and eliminates radiation exposure. It also may prevent re-stenosis from scar tissue caused by patch arterioplasty. A future direct comparison of intra-op PA stenting to catheter-based stenting and surgical arterioplasty for PA stenosis is necessary.
Cell adhesion molecules in the progression of bladder cancer: The important role of cadherins and catenins.
Authors: Patricia Torres-Galea, Peter E. Stoemmer
Journal: Journal of Clinical Oncology (2012)

e15013 Background: Cell-adhesion- molecules (CAMs) are important factors in the maintenance of normal tissue structure, morphology, aggressivity and invasivity of tumors. Few CAMs, such as E-cadherin and its substitution by N-cadherin in the progression of urothelial neoplasia are wellknown. CAMs, such as cadherin P, catenins alpha and beta are much less known..We analysed their distribution in tumors of different patients and in respect to its architecture. Methods: 100 FFPE blocks of superficial ( pTa/ pTis and pT1) and myoinvasive (&gt;pT1) carcinomas G1-3 were analysed by semiquantitative IHC- . Antibodies: E-Cadherin, P-Cadherin and Catenin Beta: Thermo Scientific, Freemont CA,USA . N-Cadherin Lab Vision, UK, Ltd, Catenin Alpha and H-CAM (CD44) Novocastra Laboratories Ltd. Results: E-Cadherin: Normal and reactive, inflammatory urothelium and dysplasia express high membranous E-cadherin-concentrations. High grade (HG) in-situ-carcinomas:discontinously ,intensively reacting cellmembranes; myoinvasive HG carcinomas lose their E-cadherin membranous component but show low diffuse intracytoplasmic reaction. N-Cadherin: in basal cells but not in normal transitional cells and LG dysplasia. High expression in HG dysplasia and deep invasive carcinomas, HG. P-cadherin:normal urothelium, as well as papillary LG and HG and CIS show an extensive membranous expression. Catenin alpha: high expression in pTa/pT1 LG tumors; low expression in myoinvasive carcinomas. Catenin beta: high membranous expression in normal and dysplastic urothelium as well as in in pTa LG tumors; low membranous cytoplasmic and intranuclear expression in myoinvasive carcinomas and HG tumors. Transition of beta-catenin from cellmembrane to nucleus in neoplasms was not visible Conclusions: E-Cadherin to N-Cadherin shift in the EMT destabilize tumorcells for CAMs, enabling by this the connection to fibrous tissues and augmenting the invasive potential. Catenins alpha and beta: strong prognosticators of progression and recidives; as they are integral parts of E-cadherin, they disappear together with E-cadherin in invasive tumor cell complexes.
Lassa virus circulating in Liberia: a retrospective genomic characterisation
Authors: Michael R Wiley, Lawrence Fakoli, Andrew G Letizia, Stephen R Welch, Jason T Ladner, Karla Prieto, Daniel Reyes, Nicole Espy, Joseph A Chitty, Catherine B Pratt, Nicholas Di Paola, Fahn Taweh, Desmond Williams, Jon Saindon, William G Davis, Ketan Patel, Mitchell Holland, Daniel Negrón, Ute Ströher, Stuart T Nichol, Shanmuga Sozhamannan, Pierre E Rollin, John Dogba, Tolbert Nyenswah, Fatorma Bolay, César G Albariño, Mosoka Fallah, Gustavo Palacios
Journal: The Lancet Infectious Diseases (2019)
Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV
Authors: Stefanie A. Ehrhardt, Matthias Zehner, Verena Krähling, Hadas Cohen-Dvashi, Christoph Kreer, Nadav Elad, Henning Gruell, Meryem S. Ercanoglu, Philipp Schommers, Lutz Gieselmann, Ralf Eggeling, Christine Dahlke, Timo Wolf, Nico Pfeifer, Marylyn M. Addo, Ron Diskin, Stephan Becker, Florian Klein
Journal: Nature Medicine (2019)
Limiting the Number of Open Records in an Electronic Health Record
Authors: Christopher T. Su
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The cost of adverse event management in patients with RAS wild-type metastatic colorectal cancer treated with first-line cetuximab and panitumumab: An Italian healthcare payer perspective
Authors: K. Patterson, S. Bhattacharyya, N. Personeni, V. Gebbia, P. Novelli, S Di Matteo, G. Colombo, C. Pescott
Journal: Annals of Oncology (2019)
Treatment outcomes of head and neck cancer patients 70 years and older receiving different chemo-radiation combinations
Authors: M. Issa, L. Mousa, D. Blakaj, B. Klamer, J. Pan, M. Old, S. Kang, R. Rupert, D. Mitchell, E. Ozer, A. Agrawal, P. Bhateja, M. Gamez, E. Miller, S. Jhawar, R. Carrau, J. Rocco, M.R. Bonomi
Journal: Annals of Oncology (2019)